Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abeona Therapeutics ( (ABEO) ) has provided an announcement.
On March 16, 2026, Abeona Therapeutics Inc.’s board approved Third Amended and Restated Bylaws, replacing bylaws last updated on July 9, 2024, to clarify rules around calling, postponing, rescheduling, or canceling annual and special shareholder meetings. The revisions also formally allow virtual meetings in line with Delaware law, remove the obligation to provide a physical shareholder list at meetings, and add provisions for attendance via remote communications.
The new bylaws significantly tighten procedural mechanics and disclosure requirements for shareholder proposals and director nominations, including those using the universal proxy framework, and raise the quorum threshold for shareholder meetings from one-third to 50% of voting shares. These changes collectively strengthen Abeona’s governance structure, potentially affecting how activists, investors, and other stakeholders engage with the company’s decision-making processes.
The most recent analyst rating on (ABEO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Abeona Therapeutics stock, see the ABEO Stock Forecast page.
Spark’s Take on ABEO Stock
According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.
The score is held down primarily by weak underlying financial performance (large operating losses and ongoing cash burn despite a stronger 2025 balance sheet) and soft technical momentum. Offsetting these is a more positive earnings-call outlook driven by reimbursement milestones (permanent J-code, broad payer coverage) and early commercialization ramp plans, though execution and adoption pace remain key risks.
To see Spark’s full report on ABEO stock, click here.
More about Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company focused on developing therapies using advanced technologies, operating under the corporate governance framework of the State of Delaware. Its shareholder and board processes are governed by bylaws that define how meetings are called, conducted, and how director nominations and stockholder proposals are handled.
Average Trading Volume: 1,205,567
Technical Sentiment Signal: Strong Sell
Current Market Cap: $259M
See more insights into ABEO stock on TipRanks’ Stock Analysis page.